Immuneering (IMRX) Payables (2020 - 2026)

Immuneering's Payables history runs 7 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• On a quarterly basis, Payables rose 10.88% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $1.5 million, a 10.88% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, down 21.23% from the prior year.
• Payables declined to $1.5 million in Q1 2026 per IMRX's latest filing, from $1.5 million in the prior quarter.
• Across five years, Payables topped out at $3.2 million in Q4 2022 and bottomed at $1.2 million in Q2 2022.
• The 5-year median for Payables is $2.0 million (2024), against an average of $2.1 million.
• Across the five-year window, Payables surged 126.24% in 2022 and plunged 42.29% in 2025, its largest moves.
• Year by year, Payables stood at $3.2 million in 2022, then tumbled by 33.06% to $2.1 million in 2023, then dropped by 7.25% to $2.0 million in 2024, then decreased by 21.23% to $1.5 million in 2025, then slipped by 5.81% to $1.5 million in 2026.
• Per Business Quant, the three latest IMRX Payables figures stand at $1.5 million (Q1 2026), $1.5 million (Q4 2025), and $1.6 million (Q3 2025).